Vaccines’ New Era-RNA Vaccine
Viruses · 2023
DOI: 10.3390/v15081760 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2023. Verfasst von Wenshuo Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: CNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China. Hauptthemen laut MEDLINE: Smallpox Vaccine, COVID-19. Die Arbeit wurde bisher 63-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Science and Technology Plan 2022, the 4th batch of an emergency special projects, Shanghai, the 18th batch of strategic emerging Industry Development special fund project, Establishment of high-throughput mRNA screening automation and platform.
Abstract (Originalsprache)
RNA vaccines, including conventional messenger RNA (mRNA) vaccines, circular RNA (circRNA) vaccines, and self-amplifying RNA (saRNA) vaccines, have ushered in a promising future and revolutionized vaccine development. The success of mRNA vaccines in combating the COVID-19 pandemic caused by the SARS-CoV-2 virus that emerged in 2019 has highlighted the potential of RNA vaccines. These vaccines possess several advantages, such as high efficacy, adaptability, simplicity in antigen design, and the ability to induce both humoral and cellular immunity. They also offer rapid and cost-effective manufacturing, flexibility to target emerging or mutant pathogens and a potential approach for clearing immunotolerant microbes by targeting bacterial or parasitic survival mechanisms. The self-adjuvant effect of mRNA-lipid nanoparticle (LNP) formulations or circular RNA further enhances the potential of RNA vaccines. However, some challenges need to be addressed. These include the technology’s immaturity, high research expenses, limited duration of antibody response, mRNA instability, low efficiency of circRNA cyclization, and the production of double-stranded RNA as a side product. These factors hinder the widespread adoption and utilization of RNA vaccines, particularly in developing countries. This review provides a comprehensive overview of mRNA, circRNA, and saRNA vaccines for infectious diseases while also discussing their development, current applications, and challenges.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CNBG-Virogin Biotech (Shanghai) Co., Ltd., Shanghai 201800, China.
- Shanghai-Virogin Biotech Co., Ltd., Shanghai 201800, China.
- Sinopharm Group China National Biotech Group (CNBG) Co., Ltd., Beijing 100124, China.
ORCID-Profile: Wenshuo Zhou, Shimiao Liao, Guohuan Yang, Li Hou, Lan Liu, William Jia
Förderung
- Shanghai Science and Technology Plan 2022, the 4th batch of an emergency special projects
- Shanghai, the 18th batch of strategic emerging Industry Development special fund project
- Establishment of high-throughput mRNA screening automation and platform
Zitieren
APA
Zhou, W., Jiang, L., Liao, S., Wu, F., Yang, G., Hou, L., Liu, L., Pan, X., Jia, W., & Zhang, Y. (2023). Vaccines’ New Era-RNA Vaccine. Viruses. https://doi.org/10.3390/v15081760
Vancouver
Zhou W, Jiang L, Liao S, Wu F, Yang G, Hou L, et al. Vaccines’ New Era-RNA Vaccine. Viruses. 2023. doi:10.3390/v15081760
BibTeX
@article{Zhou2023,
author = {Zhou, Wenshuo and Jiang, Linglei and Liao, Shimiao and Wu, Feifei and Yang, Guohuan and Hou, Li and Liu, Lan and Pan, Xinping and Jia, William and Zhang, Yuntao},
title = {Vaccines’ New Era-RNA Vaccine},
journal = {Viruses},
year = {2023},
doi = {10.3390/v15081760}
}
EUVIMED